Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
6 Results for "
bleeding risk
" in MedChemExpress (MCE) Product Catalog:
Products (6)
6 Results for "bleeding risk" in MCE Product Catalog:
Cat. No.: HY-173268
CAS No.: 3051784-94-9
Target:
Research Areas:
UNC9426 is a potent and selective TYRO3 inhibitor (IC50 = 2.1 nM), demonstrating 276-fold and 90-fold selectivity over MERTK and AXL, respectively. UNC9426 reduces platelet aggregation without increasing bleeding time and blocks TYRO3-dependent functions in tumor cells and macrophages. UNC9426 demonstrates a favorable safety profile with no significant increase in bleeding risk in vivo. UNC9426 can be used for functional studies of TYRO3-dependent phenotypes such as non-small cell lung cancer (NSCLC) .
Cat. No.: HY-144658
CAS No.: 2744293-04-5
Target:
Research Areas:
FXIa-IN-8 is a potent and selective FXIa inhibitor with an IC50 of 14.2 nM. FXIa-IN-8 shows antithrombotic activity without increasing the bleeding risk and obvious toxicitysup>[1].
Cat. No.: HY-120612
CAS No.: 1557206-59-3
Target:
Research Areas:
BMS-884775 is a selective and orally active P2Y1 antagonist with an IC50 of 0.1 nM for the human P2Y1 receptor. BMS-884775 has a similar efficacy in preventing arterial thrombosis to Clopidogrel (HY-15283) and Prasugrel (HY-15284), but treatment with BMS-884775 results in shorter bleeding time and lower bleeding risk. BMS-884775 can be used in research related to antiplatelet and arterial thrombosis-associated diseases .
Cat. No.: HY-125856A
CAS No.: 1802426-00-1
Synonyms: BMS-986177 TFA; JNJ-70033093 TFA
Target:
Research Areas:
Milvexian TFA (BMS-986177 TFA) is a factor XIa inhibitor with biological activity to prevent venous thromboembolism. Milvexian TFA was effective in reducing the occurrence of venous thromboembolism in patients undergoing knee replacement surgery. Milvexian TFA has good selectivity and shows significant inhibitory effects on plasma kallikrein and trypsin. Milvexian TFA has a bioavailability of 32%, which means it has a high absorption rate in the body. Milvexian TFA showed a relatively low risk of bleeding in clinical trials .
Cat. No.: HY-159895
Research Areas:
PAR4 antagonist 7 (Compound 20f) is selective PAR4 antagonist (IC50: 1.72 nM). PAR4 antagonist 7 inhibits PAR4 agonist-induced platelet aggregation. PAR4 antagonist 7 has good metabolic stability. PAR4 antagonist 7 does not show a bleeding tendency in mice .
Cat. No.: HY-P10577
Research Areas:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
